China NMPA Approves Uscom BP+
SYDNEY, Australia, Mon SYDNEY, Australia, Monday19th April,2021: Uscom Limited (ASX code: UCM) (the Company Company Company or Uscom) today notified the market that its patent protected high fidelity central blood pressure monitor, BP+, has received Chinese National Medical Products Administration (NMPA) approval for sale into China. The NMPA certificate will be issued within the next 10 working days.
The approval follows a rigorous 26 months’ process of testing and validation of the technology and now allows the Uscom BP+ to be sold in China, contributing a new sales revenue stream to Uscom.